<DOC>
	<DOCNO>NCT00523757</DOCNO>
	<brief_summary>Heart failure cause significant morbidity mortality rapidly increase cardiovascular diagnosis North America overall prevalence estimate 0.4 % 2.4 % . Recently , heart failure preserve ejection fraction ( HFNEF ) find 50 % patient symptomatic heart failure . Many study demonstrate HFNEF poor prognosis mortality rate 8 % per year 50 % chance needing admit hospital next year . There proven therapy type heart failure . Aldosterone blocker ( drug block hormone elevate patient heart failure ) use type heart failure . Our goal see type drug improve function heart look thickness heart muscle use MRI . Also measure amount tissue formation breakdown heart . The trial do use drug placebo see effect due drug .</brief_summary>
	<brief_title>Aldosterone Blockade Heart Failure</brief_title>
	<detailed_description>Aldosterone antagonists show efficacy systolic heart failure patient post-myocardial infarction systolic dysfunction three major randomize placebo control trial . Together trial demonstrate reduction mortality , hospitalization regression leave ventricular mass MRI . Primary Objective The primary objective study assess change marker collagen turnover correlate specific measure leave ventricular mass regression diastolic function MRI 4 month aldosterone blockade . Study Design Methods This study double-blind , conceal allocation , randomize trial University Alberta patient diastolic heart failure randomize spironolactone match placebo 4 month . Outcomes assess include LV mass MRI , collagen marker , biomarkers , clinical outcome , quality life exercise test</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . HF Framingham criteria 2 . At least one admission hospital HF within last 180 day 3 . New York Heart Association Class II thru IV 4 . Echocardiographic criterion : At least moderate diastolic dysfunction , Ejection fraction &gt; 45 % 1 . Creatinine clearance &lt; 40 mls/min/1.73m2 2 . Potassium &gt; 5.0 mmol/L 3 . Recent acute coronary syndrome prior 4 week 4 . Planned revascularization , defibrillator pacemaker next 4 month 5 . Known previous intolerance aldosterone antagonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>heart failure</keyword>
	<keyword>collagen</keyword>
	<keyword>diastolic function</keyword>
</DOC>